BD2

BD2 is one of the tandem bromodomains within bromodomain and extraterminal (BET) proteins, a family of epigenetic readers that recognize acetyl-lysine marks on chromatin and facilitate transcriptional regulation through chromatin binding.^[1][2] Mechanistically, BET bromodomains enable chromatin association that supports transcriptional programs, and BRD4 further contributes to transcriptional elongation through recruitment of positive transcription elongation factor complexes.^[2][3] Because BET proteins influence gene expression, they are implicated in cancer and other disease-associated transcriptional states.^[1][3] Disease relevance is particularly evident in BRD4-driven malignancies, including NUT midline carcinoma, where disruption of bromodomain-mediated chromatin interactions suppresses proliferation and promotes differentiation in experimental models.^[3] Compared with the related BD1 bromodomain, BD2 has emerged as a distinct pharmacological target, and selective targeting of BD1 and BD2 has demonstrated that the two bromodomains make non-identical contributions to BET protein function.^[2][4] This isoform distinction has stimulated the development of BD2-selective chemical probes and inhibitors designed to preferentially engage the second bromodomain while preserving greater selectivity than dual BD1/BD2 inhibition.^[4][5] For experimental applications, BD2-selective inhibitors provide tools to investigate BET-dependent transcriptional regulation, chromatin remodeling, oncogenic gene-expression programs, and disease-associated signaling pathways.^[4][5]